Corvus Pharmaceuticals Inc. (NASDAQ:CRVS)’s share price was up 5.9% during mid-day trading on Thursday . The company traded as high as $14.99 and last traded at $14.97, with a volume of 53,674 shares traded. The stock had previously closed at $14.14.

A number of equities analysts have issued reports on CRVS shares. Zacks Investment Research raised shares of Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Monday, June 20th. BTIG Research started coverage on shares of Corvus Pharmaceuticals in a research report on Thursday, June 2nd. They set a “buy” rating for the company. Cantor Fitzgerald started coverage on shares of Corvus Pharmaceuticals in a research report on Monday, April 18th. They set a “buy” rating and a $23.00 price target for the company. Guggenheim started coverage on shares of Corvus Pharmaceuticals in a research report on Monday, April 18th. They set a “buy” rating and a $24.00 price target for the company. Finally, Credit Suisse Group AG initiated coverage on shares of Corvus Pharmaceuticals in a research report on Monday, April 18th. They set an “outperform” rating and a $25.00 price target for the company. Six investment analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus target price of $21.60.

The company has a 50 day moving average price of $13.68 and a 200 day moving average price of $13.64. The stock’s market cap is $298.95 million.

In other Corvus Pharmaceuticals news, Director Orbimed Advisors Llc purchased 38,383 shares of the stock in a transaction that occurred on Tuesday, June 21st. The stock was purchased at an average cost of $12.75 per share, with a total value of $489,383.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder A/S Novo purchased 70,000 shares of the stock in a transaction that occurred on Thursday, May 12th. The stock was acquired at an average cost of $10.00 per share, with a total value of $700,000.00. Following the completion of the acquisition, the insider now directly owns 3,224,046 shares of the company’s stock, valued at $32,240,460. The disclosure for this purchase can be found here.

Corvus Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of agents, which target the immune system to treat patients with cancer. The Company is developing drugs and antibodies that block crucial immune checkpoints, and reprogram immune T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.